Published in Rev Infect Dis on May 17, 1991
The epidemiology of urinary tract infection. Nat Rev Urol (2010) 3.97
Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect Immun (2002) 2.20
Diagnosis and management of recurrent urinary tract infections in non-pregnant women. BMJ (2013) 2.07
Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis (2011) 1.94
Diagnosis and management of urinary tract infection in adults. BMJ (1992) 1.50
Recurrent urinary tract infections among women: comparative effectiveness of 5 prevention and management strategies using a Markov chain Monte Carlo model. Clin Infect Dis (2013) 1.45
A genetic basis of susceptibility to acute pyelonephritis. PLoS One (2007) 1.28
Invasion of cultured human epithelial cells by Klebsiella pneumoniae isolated from the urinary tract. Infect Immun (1997) 1.27
Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother (2001) 0.99
Biological Trojan horse: Antigen 43 provides specific bacterial uptake and survival in human neutrophils. Infect Immun (2006) 0.97
Ibuprofen versus mecillinam for uncomplicated cystitis--a randomized controlled trial study protocol. BMC Infect Dis (2014) 0.93
Uropathogenic Escherichia coli superinfection enhances the severity of mouse bladder infection. PLoS Pathog (2015) 0.90
Not so simple cystitis: how should prescribers be supported to make informed decisions about the increasing prevalence of infections caused by drug-resistant bacteria? Br J Gen Pract (2000) 0.88
Management of recurrent urinary tract infections in healthy adult women. Rev Urol (2013) 0.84
Prevalence and predictors of antibiotic administration during pregnancy and birth. PLoS One (2013) 0.83
Clinical and microbiological characteristics of Klebsiella pneumoniae from community-acquired recurrent urinary tract infections. Eur J Clin Microbiol Infect Dis (2014) 0.81
Molecular Epidemiology of Acute, Uncomplicated Urinary Tract Infections in Young Women. Curr Infect Dis Rep (2003) 0.79
Serum immunoglobulin response and protection from homologous challenge by Proteus mirabilis in a mouse model of ascending urinary tract infection. Infect Immun (1999) 0.79
Inflammation-Induced Adhesin-Receptor Interaction Provides a Fitness Advantage to Uropathogenic E. coli during Chronic Infection. Cell Host Microbe (2016) 0.79
Anti-inflammatory effect of an Escherichia coli extract in a mouse model of lipopolysaccharide-induced cystitis. World J Urol (2005) 0.77
Prophylaxis: recurrent urinary tract infection in women. Infection (1992) 0.77
Recurrent cystitis in nonpregnant women. West J Med (1999) 0.77
All dysuria is local. A cost-effectiveness model for designing site-specific management algorithms. J Gen Intern Med (2004) 0.76
Highly resistant metabolically deficient dwarf mutant of Escherichia coli is the cause of a chronic urinary tract infection. J Clin Microbiol (2003) 0.76
Natural history of recurrent urinary tract infections in women. Rev Infect Dis (1992) 0.75
Cystone - An ayurvedic polyherbal formulation inhibits adherence of uropathogenic E. coli and modulates H2O2-induced toxicity in NRK-52E cells. J Exp Pharmacol (2010) 0.75
The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998-2011. Open Forum Infect Dis (2017) 0.75
Non-surgical management of recurrent urinary tract infections in women. Transl Androl Urol (2017) 0.75
Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis (1989) 8.24
Effects of artemisinin derivatives on malaria transmissibility. Lancet (1996) 7.42
Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol (1985) 7.14
Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet (2000) 7.06
Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA (1992) 6.99
Neurological manifestations of dengue infection. Lancet (2000) 5.69
The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg (1996) 5.35
Qinghaosu. Lancet (1993) 5.25
Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet (1993) 5.11
Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol (1993) 4.98
Criteria for selective screening for Chlamydia trachomatis infection in women attending family planning clinics. JAMA (1986) 4.93
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet (1996) 4.90
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother (2000) 4.77
A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med (1996) 4.69
A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med (1996) 4.64
The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother (1999) 4.64
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg (2000) 4.63
Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis (1997) 4.53
The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg (1997) 4.48
Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet (2008) 4.35
Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health (2004) 4.35
Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis (1994) 4.17
Fake artesunate in southeast Asia. Lancet (2001) 3.84
Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg (1996) 3.76
The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA (1988) 3.73
Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet (1991) 3.72
A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol (1999) 3.72
Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet (2002) 3.65
Effects of Plasmodium vivax malaria in pregnancy. Lancet (1999) 3.62
Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. J Clin Pathol (1989) 3.57
Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother (2000) 3.46
Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg (2001) 3.46
Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg (1998) 3.39
Persistence of Plasmodium falciparum HRP-2 in successfully treated acute falciparum malaria. Trans R Soc Trop Med Hyg (2001) 3.32
Cardiac effects of antimalarial treatment with halofantrine. Lancet (1993) 3.32
The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol (1994) 3.23
Neurological sequelae of cerebral malaria in children. Lancet (1990) 3.11
Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg (1992) 3.10
Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med (1983) 3.07
Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet (1985) 3.03
Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol (1998) 3.02
Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg (1999) 2.98
Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg (1999) 2.94
Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria. Trans R Soc Trop Med Hyg (1993) 2.90
Molecular basis of sequestration in severe and uncomplicated Plasmodium falciparum malaria: differential adhesion of infected erythrocytes to CD36 and ICAM-1. J Infect Dis (1991) 2.87
Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med (2001) 2.83
A prospective study of asymptomatic bacteriuria in sexually active young women. N Engl J Med (2000) 2.81
Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis (2008) 2.77
Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg (2000) 2.76
Arabinose assimilation defines a nonvirulent biotype of Burkholderia pseudomallei. Infect Immun (1997) 2.72
Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am J Med (1982) 2.71
Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology (2002) 2.67
Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis (2011) 2.65
Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother (1998) 2.61
Relapse in melioidosis: incidence and risk factors. J Infect Dis (1993) 2.61
Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. J Infect Dis (1996) 2.59
Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. Trans R Soc Trop Med Hyg (1998) 2.54
Quantitative recovery of Burkholderia pseudomallei from soil in Thailand. Trans R Soc Trop Med Hyg (1996) 2.54
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother (2000) 2.54
Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features. J Clin Microbiol (2001) 2.53
High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet (1987) 2.52
The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis (1999) 2.49
Risk factors for recurrent urinary tract infection in young women. J Infect Dis (2000) 2.48
The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother (1989) 2.44
Microsatellite variation, repeat array length, and population history of Plasmodium vivax. Mol Biol Evol (2006) 2.43
The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med (2000) 2.42
The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet (1996) 2.41
Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet (1998) 2.41
Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA (1993) 2.41
Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother (2001) 2.40
The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. J Med Microbiol (1990) 2.39
The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis (2000) 2.35
Semi-quantitative measurement of Plasmodium falciparum antigen PfHRP2 in blood and plasma. Trans R Soc Trop Med Hyg (1997) 2.33
Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet (1996) 2.33
Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother (2008) 2.27
Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg (1996) 2.24
Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis (1994) 2.23
Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother (2008) 2.23
Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg (1999) 2.23
High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis (1992) 2.21
Serology and carriage of Pseudomonas pseudomallei: a prospective study in 1000 hospitalized children in northeast Thailand. J Infect Dis (1993) 2.20
Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Br J Clin Pharmacol (1996) 2.19
Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg (2007) 2.18
Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther (1999) 2.16
Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 2.16
Severe neurotoxic envenoming by the Malayan krait Bungarus candidus (Linnaeus): response to antivenom and anticholinesterase. Br Med J (Clin Res Ed) (1983) 2.15
Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet (1990) 2.14
Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. N Engl J Med (1985) 2.12
Biochemical characteristics of clinical and environmental isolates of Burkholderia pseudomallei. J Med Microbiol (1996) 2.11
Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg (2000) 2.10
Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis (1999) 2.10
Validation and application of a liquid chromatographic-mass spectrometric method for determination of artesunate in pharmaceutical samples. J Pharm Biomed Anal (2007) 2.06
Post-malaria neurological syndrome. Lancet (1996) 2.05
Systemic endothelial activation occurs in both mild and severe malaria. Correlating dermal microvascular endothelial cell phenotype and soluble cell adhesion molecules with disease severity. Am J Pathol (1998) 2.05
Intraleucocytic malaria pigment and prognosis in severe malaria. Trans R Soc Trop Med Hyg (1995) 2.03
Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. Blood (1996) 2.01
Effects of malaria during pregnancy on infant mortality in an area of low malaria transmission. Am J Epidemiol (2001) 2.01
A review of the spectrum of clinical ocular fundus findings in P. falciparum malaria in African children with a proposed classification and grading system. Trans R Soc Trop Med Hyg (2000) 2.00
Parasite multiplication potential and the severity of Falciparum malaria. J Infect Dis (2000) 2.00